A Phase 3, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a SARS‑CoV‑2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine with Matrix-M™ Adjuvant and a Standalone Trivalent Hemagglutinin Nanoparticle Influenza Vaccine with Matrix-M Adjuvant in Participants ≥ 60 years of Age
